Document is current
Any future updates will be listed below
-
Authors
Suzuki, Kenichi
Yokokawa, Takashi https://orcid.org/0000-0001-9988-128X
Kawaguchi, Takashi
Takada, Shinya
Tamaki, Shinya
Kawasaki, Yohei
Yamaguchi, Takumi
Koizumi, Kei
Matsumoto, Takuma
Sakata, Yukio
Arakawa, Yuichiro
Ayuhara, Hideaki
Hosonaga, Mari
Yamaguchi, Masakazu
Tsuji, Daiki https://orcid.org/0000-0001-8894-2841
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000038644 at UMIN JapanDocuments that mention this clinical trial
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)
https://doi.org/10.1038/s41598-024-79781-6
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 12 November 2024
First Online: 16 November 2024
Declarations
:
: The authors declare no competing interests.
: This study was conducted in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects published by Japan’s Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written, informed consent was obtained from all participants.
